Hemophilia Treatment Market Expected to Reach $26.9 Billion by 2031

Hemophilia treatment market size was valued at $12.8 billion in 2021, and is estimated to reach $26.9 billion by 2031, growing at a CAGR of 7.5% from 2022 to 2031. Hemophilia is a bleeding disorder that slows the blood clotting process. People with this condition experience prolonged bleeding or oozing following an injury, surgery, or having a tooth pulled. In severe cases of hemophilia, continuous bleeding occurs after minor trauma or even when there is no obvious injury. Serious complications in the joints, muscles, brain, or other internal organs can result from bleeding. Milder forms of hemophilia do not necessarily involve spontaneous bleeding, and the condition may not become apparent until abnormal bleeding occurs following surgery or a serious injury. The primary treatment for severe hemophilia involves replacing the clotting factor needed through a tube in a vein.
𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
Bayer AG, Pfizer, Inc., F. Hoffmann-La Roche AG, CSL Ltd., Takeda Pharmaceuticals Company Ltd., Novo Nordisk A/S, Grifols S.A., Swedish Orphan Biovitrium AB, Octapharma AG, and Medexus Pharmaceuticals Inc.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/301
𝗖𝗼𝘃𝗶𝗱-𝟭𝟵 𝗦𝗰𝗲𝗻𝗮𝗿𝗶𝗼:
Coronavirus (COVID-19) was discovered in late December 2019 in Hubei province of Wuhan city in China. The situation of COVID-19 has varied outcome when related to vaccinations. There is an emerging gap in the economic recovery between high-income and low and middle income countries. After the pandemic severely disrupted global trade, the world is witnessing a robust rebound, which helped with the recovery in 2021. Trade contributes to speeding up economic recovery from the pandemic by providing sustained foreign demand for exports and ensuring the availability of imported intermediate products and services. Amidst the initial outbreak of COVID-19, the outlook for the hemophilia treatment industry was negatively impacted by the COVID-19 pandemic. It was thought that hemophilia patients were more prone to COVID-19, which made them more precautious and subjected to avoid the hospitals visits in early 2020. This led to decrease in the use of hemophilia medicines. Moreover, the supply chain of the medicines was also disturbed, which led to increase in demand and supply gap. In addition, manufacturers were also made to slow down the manufacturing procedure due to the limitations on the numbers of workers allowed. However, the situation of reduced usage of hemophilia medicines is observed to be changing in the 2021 and is expected to totally increase the supply and demand in the near future post pandemic. Overall, the COVID-19 pandemic had a negative impact on the hemophilia treatment market size owing to the various stringent government restrictions for reducing hospital visits. The manufacturers were also hit by the pandemic effect with decrease in demand for hemophilia medicines.
𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/301
On the basis of type, the hemophilia treatment market is categorized as hemophilia A and hemophilia B. The hemophilia A segment was dominant in 2021 and is expected to remain dominant during the forecast period, owing to the rise in incidence of hemophilia A and increased use of factor VIII. Hemophilia A is also projected to exhibit the fastest market growth during the forecast period, owing to technological advancements in treatment of hemophilia and product approval by regulating authorities.
On the basis of drug therapy, the recombinant coagulation factor concentrates therapy segment was dominant in 2021 and is expected to remain dominant during the forecast period, owing to increase in the number of recombinant technology products available for the treatment. Moreover, non-factor replacement therapy is projected to exhibit the fastest growth during hemophilia treatment market forecast period, owing to increase in target population and rise in R&D activities on the treatment therapies.
𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘
By type, the hemophilia A segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 7.6% from 2022 to 2031.
By drug therapy, the non-factor replacement therapy segment is expected to experience growth at the highest rate, registering a CAGR of 8.6% during the forecast period of the hemophilia treatment market analysis.
Region-wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 8.3% during the forecast period of the hemophilia treatment market analysis.
𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Point of Care Diagnostics Market -- https://www.alliedmarketresearch.com/point-of-care-diagnostics-market

Biomaterials Market -- https://www.alliedmarketresearch.com/biomaterials-market

Contact Us:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

This release was published on openPR.